Drugs / SHR-4658
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07230145 | Nov 2025 → Jun 2026 overdue | heart failure | Beijing Suncadia Pharmaceuticals Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-4658 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07230145 ↗ |
| Route | Subcutaneous | “single subcutaneous injection of SHR-4658” NCT07230145 ↗ |